Nurix Therapeutics (NRIX)
NASDAQ:NRIX
Top Page
Nurix Therapeutics
(NASDAQ:NRIX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$15.00
▼(-5.00% Downside)
Action:ReiteratedDate:03/07/26
The score is primarily held back by weak financial performance—large operating losses and deep negative free cash flow that imply ongoing financing needs—despite a comparatively supportive balance sheet. Technicals also lean bearish (negative MACD, low RSI, and price below key short- and mid-term moving averages). Offsetting these risks, corporate updates point to meaningful clinical progress, though the expanded ATM program underscores dilution risk.
Positive Factors
Clinical efficacy of lead BTK degrader
Robust Phase 1 data (83% ORR) and initiation of the DAYBreak-201 pivotal Phase 2 create a durable clinical pathway toward accelerated approval for CLL. This improves the probability of a registrational outcome, strengthens commercialization potential, and supports long-term franchise value in B‑cell malignancies.
Negative Factors
High cash burn
Sustained, large negative operating and free cash flows reflect heavy R&D and trial spending. Persistent burn requires continued external financing or partnerships, increasing dilution and execution risk if clinical timelines slip or capital markets tighten, pressuring long‑term financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy of lead BTK degrader
Robust Phase 1 data (83% ORR) and initiation of the DAYBreak-201 pivotal Phase 2 create a durable clinical pathway toward accelerated approval for CLL. This improves the probability of a registrational outcome, strengthens commercialization potential, and supports long-term franchise value in B‑cell malignancies.
Read all positive factors
Nurix Therapeutics (NRIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.60B
Dividend YieldN/A
Average Volume (3M)1.17M
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue Growth48.32%
EPS Growth-1.91%
CountryUS
Employees286
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.82
Shares Outstanding102,843,010
10 Day Avg. Volume1,669,026
30 Day Avg. Volume1,165,014
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue14.02
Enterprise Value/Gross Profit-16.04
Enterprise Value/Ebitda-4.58
Forecast
1Y Price Target
$31.00Price Target Upside96.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.13
Revenue Forecast (FY)$57.76M
Nurix Therapeutics Business Overview & Revenue Model
Company Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bru...
How the Company Makes Money
Nurix Therapeutics generates revenue primarily through a combination of partnerships, collaborations, and funding from research grants. The company often enters into strategic collaborations with larger pharmaceutical companies, which can include ...
Nurix Therapeutics Key Performance Indicators (KPIs)
Nurix Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 83.98M | 54.55M | 76.99M | 38.63M | 29.75M |
| Gross Profit | 65.12M | -167.08M | -112.16M | -145.87M | -86.68M |
| EBITDA | -244.84M | -205.01M | -148.93M | -179.72M | -115.90M |
| Net Income | -264.46M | -193.57M | -143.95M | -180.36M | -117.19M |
Balance Sheet | |||||
| Total Assets | 688.13M | 669.34M | 355.60M | 416.76M | 476.77M |
| Cash, Cash Equivalents and Short-Term Investments | 592.94M | 609.58M | 287.91M | 309.14M | 295.72M |
| Total Debt | 55.73M | 28.30M | 30.61M | 11.96M | 13.04M |
| Total Liabilities | 149.39M | 142.35M | 155.10M | 113.06M | 134.47M |
| Stockholders Equity | 538.75M | 526.99M | 200.49M | 303.70M | 342.30M |
Cash Flow | |||||
| Free Cash Flow | -263.47M | -181.86M | -89.77M | -172.05M | -90.03M |
| Operating Cash Flow | -249.47M | -172.58M | -81.36M | -159.81M | -84.36M |
| Investing Cash Flow | 147.85M | -257.71M | 68.30M | 27.20M | -108.25M |
| Financing Cash Flow | 238.64M | 485.67M | 3.22M | 117.19M | 153.88M |
Nurix Therapeutics Technical Analysis
Positive
15.79
Price Trends
15.96
Negative
16.74
Negative
13.68
Positive
Market Momentum
-0.14
Negative
53.52
Neutral
65.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Positive. The current price of 15.79 is above the 20-day moving average (MA) of 15.25, below the 50-day MA of 15.96, and above the 200-day MA of 13.68, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 53.52 is Neutral, neither overbought nor oversold. The STOCH value of 65.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NRIX.
Nurix Therapeutics Risk Analysis
Nurix Therapeutics disclosed 81 risk factors in its most recent earnings report. Nurix Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nurix Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.45B | -1.91 | -49.31% | ― | -78.55% | 7.74% | |
62 Neutral | $6.09B | -39.12 | -20.02% | ― | ― | 12.45% | |
56 Neutral | $2.23B | -5.25 | -43.17% | ― | -16.50% | 33.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $717.64M | -9.53 | -14.25% | ― | ― | ― | |
47 Neutral | $1.60B | ― | -57.51% | ― | 48.32% | -1.91% |
* Healthcare Sector Average
NRIX
Nurix Therapeutics
15.79
6.07
62.45%
ARVN
Arvinas Holding Company
11.22
4.85
76.14%
VIR
Vir Biotechnology
9.06
3.54
64.13%
RLAY
Relay Therapeutics
12.45
10.40
507.32%
TERN
Terns Pharmaceuticals
52.78
50.78
2539.00%
Nurix Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Nurix Therapeutics Expands ATM Equity Offering Capacity
Positive
Mar 6, 2026
On March 6, 2026, Nurix Therapeutics amended its existing equity distribution agreement with Piper Sandler, allowing the biotech company to offer and sell up to $413.65 million of its common stock through at-the-market offerings. The total include...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Nurix Therapeutics Outlines 2026 Goals and Pipeline Progress
Positive
Jan 12, 2026
On January 12, 2026, Nurix Therapeutics presented its 2025 performance and 2026 goals at the 44th Annual J.P. Morgan Healthcare Conference, highlighting 2025 as a breakthrough year marked by significant clinical, partnering, and financing mileston...
Business Operations and StrategyProduct-Related Announcements
Nurix Therapeutics Reports Promising Data at Hematology Meeting
Positive
Dec 9, 2025
On December 6 and 8, 2025, Nurix Therapeutics announced new clinical data from its Phase 1a/1b study of the BTK degrader bexobrutideg (NX-5948) at the 67th American Society of Hematology Annual Meeting. The data showed promising efficacy and safet...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.